At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 228 enrolled
Drug / intervention
Everolimus (RAD001) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
In Brief
A Phase 4 clinical trial evaluating Everolimus (RAD001), Tacrolimus, and 2 other interventions for Renal Transplantation. Completed, enrolled 228 participants across 1 site.
Detailed Summary
This study is designed to evaluate whether tacrolimus dose reduction in de novo renal recipients receiving everolimus can preserve renal function while maintaining efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplantation
CountriesSwitzerland
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedAug 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedAug 29, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.8 years ago
Interventions
Everolimus (RAD001)drug
Tacrolimusdrug
Basiliximabdrug
Corticosteroidsdrug